A Randomized, Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)
This randomized phase II/III trial studies how well afatinib dimaleate with cetuximab works
and compares it with afatinib dimaleate alone in treating patients with newly diagnosed stage
IV or recurrent (has come back), epidermal growth factor receptor (EGFR) mutation positive
non-small cell lung cancer. Afatinib dimaleate may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may
block tumor growth in different ways by targeting certain cells. It is not yet known whether
afatinib dimaleate is more effective when given alone or with cetuximab in treating patients
with non-small cell lung cancer.
Manchester,Nashua,St. Johnsbury, VT
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.